Profil Institute Publishes White Paper Series Focused on the Current State of Diabetes, Obesity and NAFLD/NASH Clinical Research and Development

Profil Institute Publishes White Paper Series Focused on the Current State of Diabetes, Obesity and NAFLD/NASH Clinical Research and Development

SAN DIEGO, October 8, 2015 /PRNewswire/ –  Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the launch of its white paper series focused on current developments in clinical research, biomarker development and disease management.

The company’s white papers, named Profil Focus Papers, narrow in on one area of expertise and are authored by key scientific thought leaders. The most recent Focus Papers of this series are titled:

  • Current and Future Perspectives on the Development of Biosimilar Insulins for Diabetes Management
  • Considerations for Evaluating the Cardiovascular Safety of Novel Treatments for Diabetes
  • Recruitment Considerations for Early Phase Clinical Trials in Diabetes

The papers are available for download from Profil Institute’s online Knowledge Library.  Additional Focus Papers on topics related to diabetes, obesity and NAFLD/NASH will be added regularly.

About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, visit www.profilinstitute.com.

For further information, please contact:
Abby Devine
Profil Institute for Clinical Research, Inc.
Corporate Communications
abby.devine@profilinstitute.com
+1 (858) 663-6148